Spots Global Cancer Trial Database for Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60

Official Title: A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Elderly Newly Diagnosed Acute Myeloid Leukemia Patients.

Study ID: NCT04083911

Conditions

Acute Myeloid Leukemia

Induction Chemotherapy

Interventions

Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF

Study Description

Brief Summary: The purpose of this study is to evaluate the safety and efficacy of DAC combined with HAAG regimen in the induction treatment of newly diagnosed AML patients older than 60 years.

Detailed Description: This is a phase 3, open Label, single arm, multi-center study in elderly newly diagnosed AML patients. The patients will receive DAC combined with HAAG in the induction treatment.